Filing Flows › Generate Biomedicines (GENB) › Next earnings date
Generate Biomedicines (GENB) earnings on Nov 10, 2026: what to expect
Generate Biomedicines (GENB) is expected to report earnings on Nov 10, 2026 (estimated), in 2 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.55 (−$0.67 to −$0.44, 4 estimates) on revenue of $7.8M. It beat the EPS estimate in 0% of the quarters on record; Filing Flows' model gives it a 50% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
The last report
Generate Biomedicines reported revenue of $6.3M for the second quarter 2026 (-38% Y/Y), net loss $67.3M. How it makes money → · Every quarter →
Generate Biomedicines' latest quarter
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
Questions
When does GENB report earnings?
Generate Biomedicines is expected to report on Nov 10, 2026 (estimated).
What are analysts expecting from Generate Biomedicines?
EPS of −$0.55 and revenue of $7.8M for the quarter.
Does Generate Biomedicines usually beat earnings?
It beat the consensus EPS estimate in 0% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.